Literature DB >> 1763060

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

D Papahadjopoulos1, T M Allen, A Gabizon, E Mayhew, K Matthay, S K Huang, K D Lee, M C Woodle, D D Lasic, C Redemann.   

Abstract

The results obtained in this study establish that liposome formulations incorporating a synthetic polyethylene glycol-derivatized phospholipid have a pronounced effect on liposome tissue distribution and can produce a large increase in the pharmacological efficacy of encapsulated antitumor drugs. This effect is substantially greater than that observed previously with conventional liposomes and is associated with a more than 5-fold prolongation of liposome circulation time in blood, a marked decrease in uptake by tissues such as liver and spleen, and a corresponding increased accumulation in implanted tumors. These and other properties described here have expanded considerably the prospects of liposomes as an effective carrier system for a variety of pharmacologically active macromolecules.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763060      PMCID: PMC53155          DOI: 10.1073/pnas.88.24.11460

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs.

Authors:  R L Juliano; D Stamp
Journal:  Biochem Biophys Res Commun       Date:  1975-04-07       Impact factor: 3.575

2.  Recent advances in sustained release of antineoplastic drugs using liposomes which avoid uptake into the reticuloendothelial system.

Authors:  T M Allen; T Mehra
Journal:  Proc West Pharmacol Soc       Date:  1989

3.  Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues.

Authors:  T M Allen; C Hansen; J Rutledge
Journal:  Biochim Biophys Acta       Date:  1989-05-19

4.  Liposomes for the sustained drug release in vivo.

Authors:  G Blume; G Cevc
Journal:  Biochim Biophys Acta       Date:  1990-11-02

5.  Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study.

Authors:  A Gabizon; T Peretz; A Sulkes; S Amselem; R Ben-Yosef; N Ben-Baruch; R Catane; S Biran; Y Barenholz
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

6.  Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages.

Authors:  J T Derksen; H W Morselt; G L Scherphof
Journal:  Biochim Biophys Acta       Date:  1988-09-16

7.  Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface.

Authors:  T M Allen; P Williamson; R A Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

8.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Authors:  A Gabizon; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

9.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.

Authors:  A Gabizon; R Shiota; D Papahadjopoulos
Journal:  J Natl Cancer Inst       Date:  1989-10-04       Impact factor: 13.506

10.  Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections.

Authors:  J P Sculier; A Coune; F Meunier; C Brassinne; C Laduron; C Hollaert; N Collette; C Heymans; J Klastersky
Journal:  Eur J Cancer Clin Oncol       Date:  1988-03
View more
  304 in total

1.  Supramolecular materials via polymerization of mesophases of hydrated amphiphiles.

Authors:  Anja Mueller; David F O'Brien
Journal:  Chem Rev       Date:  2002-03       Impact factor: 60.622

2.  Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.

Authors:  U Beyer; B Rothern-Rutishauser; C Unger; H Wunderli-Allenspach; F Kratz
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

3.  Interaction of cationic colloids at the surface of J774 cells: a kinetic analysis.

Authors:  P Chenevier; B Veyret; D Roux; N Henry-Toulmé
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

4.  In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™.

Authors:  Wubeante Yenet Ayen; Neeraj Kumar
Journal:  Pharm Res       Date:  2012-06-06       Impact factor: 4.200

Review 5.  Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

Authors:  William C Zamboni; Vladimir Torchilin; Anil K Patri; Jeff Hrkach; Stephen Stern; Robert Lee; Andre Nel; Nicholas J Panaro; Piotr Grodzinski
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

6.  Liposome-mediated therapy of intracranial brain tumors in a rat model.

Authors:  U S Sharma; A Sharma; R I Chau; R M Straubinger
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 7.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

8.  Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery.

Authors:  Jamie L Betker; Dallas Jones; Christine R Childs; Karen M Helm; Kristina Terrell; Maria A Nagel; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2018-07-17       Impact factor: 9.776

9.  Development of anti-p185HER2 immunoliposomes for cancer therapy.

Authors:  J W Park; K Hong; P Carter; H Asgari; L Y Guo; G A Keller; C Wirth; R Shalaby; C Kotts; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model.

Authors:  Hugo Oliveira; Julie Thevenot; Elisabeth Garanger; Emmanuel Ibarboure; Pilar Calvo; Pablo Aviles; Maria Jose Guillen; Sébastien Lecommandoux
Journal:  Pharm Res       Date:  2013-11-28       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.